Elira, a startup from St. Louis, Missouri, recently received their second patent in the AI Biotech space. The company recognizes the issue of obesity in America, and believes they have a solution. They are focused on using a transcutaneous electric patch in driving weight loss and appetite suppression when coupled with an integrated weight loss reduction strategy. They seem to be one of the only using AI in this way. The company is currently wrapping up their second clinical trial (the first was terminated early) and results are expected within the next year. Depending on the results, this technology could both be developed further or expanded to other therapeutic areas.
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.